Therapeutic inhibitor of vascular smooth muscle cells
View Patent ↗Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
1. A method for maintaining vessel luminal area following vascular trauma, comprising: administering to a mammal an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount that has a minimal effect on protein synthesis and allows for vascular repair.
2. The method of claim 1 , wherein the sustained release dosage form comprises biodegradable microparticles, biodegradable nanoparticles or a mixture thereof.
3. The method of claim 1 , wherein the sustained release dosage form comprises a cytoskeletal inhibitor.
4. The method of claim 1 , wherein the sustained release dosage form comprises a cytochalasin or a cytochalasin analog.
5. The method of claim 1 , wherein the sustained release dosage form comprises taxol or a taxol analog.
6. The method of claim 1 , wherein the cytostatic amount of the sustained release dosage form does not exhibit substantial cytotoxicity.
7. The method of claim 1 , wherein the administration inhibits vessel stenosis or restenosis.
8. The method of claim 1 , wherein the administration is local.
9. A method for maintaining vessel luminal area, comprising: administering to a mammalian vessel an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount which allows for cellular repair and extracellular matrix production.
10. The method of claim 9 , wherein the sustained release dosage form comprises biodegradable microparticles, biodegradable nanoparticles or a mixture thereof.
11. The method of claim 9 , wherein the sustained release dosage form comprises a cytoskeletal inhibitor.
12. The method of claim 9 , wherein the sustained release dosage form comprises a cytochalasin or a cytochalasin analog.
13. The method of claim 9 , wherein the sustained release dosage form comprises taxol or a taxol analog.
14. The method of claim 9 , wherein the cytostatic amount of the sustained release dosage form does not exhibit substantial cytotoxicity.
15. The method of claim 9 , wherein the administration inhibits vessel stenosis or restenosis.
16. The method of claim 9 , wherein the administration is local.
17. A method for maintaining vessel luminal area, comprising: administering to a mammalian vessel an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount which allows for cellular repair and extracellular matrix production, wherein the dosage form comprises a cytochalasin or a cytochalasin analog.